T1	Participants 65 107	patients receiving intravenous antibiotics
T2	Participants 404 465	patient group receiving prolonged courses of i.v. antibiotics
T3	Participants 625 654	Patients with cystic fibrosis
T4	Participants 946 970	hep/hc and filter groups
T5	Participants 1441 1454	patient group
T6	Participants 1611 1653	patients requiring longer term i.v. access
